Arca Biopharma | ABIO - Cash And Equivalent

Arca Biopharma reported $53.36M in Cash and Equivalent for its fourth fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Cash And Equivalent Change
Amgen AMGN:US USD 9.3B 197M
Biogen BIIB:US USD 3.42B 256.3M
Brainstorm Cell Therapeutics BCLI:US USD 4.14M 4.86M
Bristol Myers Squibb BMY:US USD 9.12B 1.39B
Capricor Therapeutics CAPR:US USD 41.42M 33.01M
Cytokinetics CYTK:US USD 65.58M 40.66M
Cytrx CYTR:US USD 5.08M 1.69M
Daiichi Sankyo 4568:JP JPY 395.18B 85.04B
Gilead Sciences GILD:US USD 7.63B 2.93B
GlaxoSmithKline GSK:LN GBP 3.72B 117M
Laboratory Of America LH:US USD 430M 20.1M
Myriad Genetics MYGN:US USD 3.3M 49.6M
Otsuka Holdings 4578:JP JPY 471.63B 5.66B
United Therapeutics UTHR:US USD 961.2M 5.6M